sunbet

sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
Á¬Ã¦ËÑË÷
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
Á¬Ã¦ËÑË÷
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
ÂýÐÔñ²ðﶯÎïÄ£×Ó
Ä¿½ñλÖãºÊ×Ò³ > ÈËÀ༲²¡¶¯ÎïÄ£×ÓĿ¼ > Éñ¾­ÏµÍ³Ä£×Ó > ÂýÐÔñ²ðﶯÎïÄ£×Ó

ǰÑÔ

ÂýÐÔñ²ðïÄ£×ÓÄܹ»·´Ó¦ñ²ðﱬ·¢µÄÆðʼ¡¢Éú³¤ÒÔ¼°ÅãͬµÄÄÔ²¿²¡ÀíÐÄÀíµÄ¸Ä±ä£¬ÕâΪԽ·¢ÉîÈëÑо¿ñ²ðïÌṩÁË»ù´¡¡£Æ¾Ö¤¸øÓè´Ì¼¤µÄÇ¿¶ÈºÍÓÕ·¢µÄ²¡ÇéˮƽµÄ²î±ð£¬¿É·ÖΪµãȼģ×Ó¡¢Ò»Á¬ÐÔñ²ðïÄ£×ÓºÍ×Ô¾õÐÔñ²ðïÄ£×Ó¡£

 

²¿·ÖÔìÄ£ÒªÁì

ʹÓö¯ÎСÊó¡¢´óÊó

¡¾ÔìÄ£»úÖÆ¡¿£º

µãȼģ×ÓÊÇÖ¸ÖØ¸´³õʼµÄÑǾªØÊ¼ÁÁ¿µÄ´Ì¼¤£¨µç£¯»¯Ñ§Ò©Îï´Ì¼¤£©ÇðÄԺͺ£ÂíµÈ²¿Î»£¬Öð½¥½µµÍ¾ªØÊ±¬·¢·§Öµ²¢Ìá¸ßÃô¸ÐÐÔ£¬ÂÄÀúÒ»¸ö´Ó²¿·ÖÐÔ±¬·¢(1~3¼¶)µ½È«Éí±¬·¢(4~5¼¶£©µÄÂýÐÔÀú³Ì£¬×îÖÕÌåÏÖÎªÖØ¸´¡¢×Ô¾õ±¬·¢¡£

¡¾Ä£×ÓÒªÁìºÍÄ£×ÓÌØµã¡¿£º

1. µç´Ì¼¤µãȼģ×Ó ÊÇÑо¿ñ²ðﱬ·¢ÆøÖÆÊ¹ÓÃ×î¶àµÄÖØ´ó²¿·ÖÐÔÄ£×Ó ÄÜ·ñ·ºÆðµãȼȡ¾öÓڴ̼¤Ò»Á¬Ê±¼ä¡¢Ç¿¶È¡¢´Ì¼¤¾àÀëʱ¼äµÈ²ÎÊý¡£±ê×¼µÄ´Ì¼¤Ìõ¼þΪµçÁ÷Ç¿¶È3mA£¬Ò»Á¬2Ã룬1´Î£¯ÈÕ£¨Ð¡Ê󣩣»8mA£¬Ò»Á¬4Ã룬2´Î£¯ÈÕ£¨´óÊ󣩣¬Ö±ÖÁ·ºÆð5¼¶±¬·¢£¬¼´±»ÒÔΪµÖ´ïÍêÈ«µãȼ¡£Ñ¡È¡Ò»Á¬10´ÎµÖ´ï5¼¶±¬·¢µÄ´óÊóÓÃÓÚɸѡ¿¹²¡Ò©¼°»úÖÆÑо¿¡£ µãȼÀú³Ì¿É·ÖΪ6¸ö½×¶Î£º¢Ùͬ²àÃæ²¿³é´¤£»¢ÚÁ½²àÃæ²¿³é´¤£»¢Ûò¥Ê×£»¢Ü¶Ô²àǰ֫·ºÆðÕóÂΣ»¢ÝÕ¾Á¢°éÕóÂÎÐÔÌøÔ¾£»¢Þˤµ¹°éÈ«Éíǿֱ£­ÕóÂα¬·¢¡£µç´Ì¼¤ÄÔ²¿Ðí¶à²¿Î»¿ÉÒýÆðµãȼ£¬×îÒ×µãȼ²¿Î»ÎªÐÓÈʺˣ¬Æä´ÎΪÐÂÆ¤ÖÊÇøºÍº£Âí¡£

2. »¯Ñ§µãȼģ×Ó£­ÂíÉ£ÄÚõ¥µãȼģ×Ó ÂíÉ£ÄÚõ¥(coriaria lactone)1.25~1.75mg/kg¼¡ÄÚ»ò¸¹Ç»×¢É䣬1´Î£¯84Сʱ£¬Æ½¾ùΪ15´Î(7~20´Î)¡£µÚ8´Î¸øÒ©ºó£¬¶¯Îï·ºÆð×¢ÊÓ¡¢ºôÎü¼±´Ù¡¢Íâ¶ú¾²ÂöÀ©ÕÅ£¬Ö®ºóÉú³¤ÎªÔ˶¯²»Ð­µ÷¡¢Ã沿³é´¤¡¢´¥Ðë²ü¶¶¡¢Ç°Ö«³é¶¯£¨±¬·¢¼¶±ðΪ1~3¼¶£©£¬°éÓм¬²¨ºÍ¶à¼¬²¨¡£ÍêÈ«µãȼ´óÊóÌåÏÖΪվÁ¢°éË«ÉÏÖ«³é¶¯(4¼¶)ºÍʧȥ×ËÊÆÆ½ºâ¡¢Ë¤µ¹(5¼¶£©£¬×îÖÕÌåÏÖΪȫÉíǿֱ£­ÕóÂα¬·¢£¬Ò»Á¬10~20Ã룬ÄÔµçͼ(EEG)ÌåÏÖΪ¸ß²¨·ù²¡ÐԷŵç¡£¸ÃÄ£×Ó²¡Àí¸Ä±äÖ÷ҪΪº£ÂíÇøÐÇÐνºÖÊϸ°ûÏÔ×űäÐÔ¡¢»µËÀ£¬ÌáÐÑÂíÉ£ÄÚõ¥¶ÔÐÇÐνºÖÊϸ°ûºÍ´óÄÔÆ¤ÖÊϸ°ûÓÐËðÉËÐÔ×÷Ó㬸ÃËðÉË¿ÉÄÜÔÚÓÕµ¼ñ²ðﱬ·¢ÖÐÆðÒ»¶¨×÷Ó᣸ÃÄ£×Ó½¨ÉèÇáÓ¯£¬µãȼЧÂʸߣ¬éæÃüÂʵͣ¬ÊÊÓÚÍÆ¹ã¡£

¡¾Ä£×ÓÆÀ¹ÀºÍÓ¦Óá¿£º

µãȼģ×ÓÐÐΪ¹æ·¶£¬¿É¿ØÐÔºÍÖØ¸´ÐԺã¬Ò×ÓÚ¶ÏÓ붨Á¿Ñо¿¡£ÎªÑо¿ÈËÀàñ²ðﱬ·¢ÆøÖÆ¡¢Ò©ÎïÓÐÓÃÐÔ¼°¿¹ñ²ðïÒ©ÎïÄÍÒ©µÄ·Ö×Ó»úÖÆ£¬Ñ°ÕÒеĻò¸üÓÐÓõÄÖÎÁÆÒ©ÎÌṩÁËÒ»¸öÀíÏëµÄ¶¯ÎïÄ£×Ó¡£´ËÄ£×ӽϺõØÄ£ÄâÁËÈËÀàñ²ðﱬ·¢¡¢À©²¼ºÍÐγɵÄÈ«Àú³Ì£¬Òò´Ë£¬±»ÒÔΪÊǸüΪ¿¿½üÈËÀàñ²ðïµÄÂýÐÔÄ£×Ó¡£µãȼģ×Ó±»ÆÕ±éÓÃÓÚѰÕÒÖÎÁƲ¿·ÖÐÔ±¬·¢µÄÐÂÒ©£¬ÔÚµãȼÀú³ÌÖÐÔ¤ÏȸøÓèËù²âÊÔµÄÒ©ÎÊÓ²ì¸ÃÒ©ÎïÄÜ·ñ×èÖ¹»òÑÓ»ºµãȼÕ÷ÏóµÄ±¬·¢£¬ÒÔ¼ì²â¸ÃÒ©ÊÇ·ñ¾ßÓп¹¾ªØÊ×÷Óúͣ¨»ò£©¿¹ñ²ðïÔîÐγɵÄ×÷Óá£

 

²Î¿¼ÎÄÏ×£º

1.Andrè V, Dube C, Francois J, et al. Pathogenesis and pharmacology of epilepsy in the lithium-pilocarpine model. Epilepsia,2007,48 (Suppl 5):41-47

2.Gareri P, Condorelli D, Bellua.rdo N, el al. Antiabsence effects of carbenoxolone in two genetic animal models of absence epilepsy (WAG/Rij rats and lh/lh mice).Neuropharmacology, 2005, 49 (4):551-563

3.Holmes GL. Animal model studies application to human patients. Neurology, 2007, 69 (24 Suppl 3): S28-32

4.Jefferys JG. Models and mechanisms of experimental epilepsies. Epilepsia, 2003, 44 (Suppl 12):44-50

5.Löscher W,Leppik IE. Critical re-evaluation of previous preclinical strategies for the cliscovery and the development of new anliepileplic drugs. Epilepsy Res, 2002, 50 (1-2):17-20

6.Löscher W,Schmidt D.Stralegies in aatiepileptic drug development: is rational drug design superior to random screening and structural variation?Epilepsy Res, 1994, 17 (2):95-134

7.Wang Y, Zhou D, Wang B, el al. A kindling model of pharmacoresislanl temporal lobe epilepsy in SpragueDawley rats induced by Coriaria lactone and its possible mechanism. Epilepsia,2003,44(4):475-488

8.White HS. Preclinical development of antiepileptic drugs: past, present, and future directions. Epilepsia, 2003, 44 (Suppl 7):2-8

sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
Ä£×ÓĿ¼
Ä¿½ñλÖãºÊ×Ò³ > ÈËÀ༲²¡¶¯ÎïÄ£×ÓĿ¼ > Éñ¾­ÏµÍ³Ä£×Ó > ÂýÐÔñ²ðﶯÎïÄ£×Ó
ÂýÐÔñ²ðﶯÎïÄ£×Ó

ǰÑÔ

ÂýÐÔñ²ðïÄ£×ÓÄܹ»·´Ó¦ñ²ðﱬ·¢µÄÆðʼ¡¢Éú³¤ÒÔ¼°ÅãͬµÄÄÔ²¿²¡ÀíÐÄÀíµÄ¸Ä±ä£¬ÕâΪԽ·¢ÉîÈëÑо¿ñ²ðïÌṩÁË»ù´¡¡£Æ¾Ö¤¸øÓè´Ì¼¤µÄÇ¿¶ÈºÍÓÕ·¢µÄ²¡ÇéˮƽµÄ²î±ð£¬¿É·ÖΪµãȼģ×Ó¡¢Ò»Á¬ÐÔñ²ðïÄ£×ÓºÍ×Ô¾õÐÔñ²ðïÄ£×Ó¡£

 

²¿·ÖÔìÄ£ÒªÁì

ʹÓö¯ÎСÊó¡¢´óÊó

¡¾ÔìÄ£»úÖÆ¡¿£º

µãȼģ×ÓÊÇÖ¸ÖØ¸´³õʼµÄÑǾªØÊ¼ÁÁ¿µÄ´Ì¼¤£¨µç£¯»¯Ñ§Ò©Îï´Ì¼¤£©ÇðÄԺͺ£ÂíµÈ²¿Î»£¬Öð½¥½µµÍ¾ªØÊ±¬·¢·§Öµ²¢Ìá¸ßÃô¸ÐÐÔ£¬ÂÄÀúÒ»¸ö´Ó²¿·ÖÐÔ±¬·¢(1~3¼¶)µ½È«Éí±¬·¢(4~5¼¶£©µÄÂýÐÔÀú³Ì£¬×îÖÕÌåÏÖÎªÖØ¸´¡¢×Ô¾õ±¬·¢¡£

¡¾Ä£×ÓÒªÁìºÍÄ£×ÓÌØµã¡¿£º

1. µç´Ì¼¤µãȼģ×Ó ÊÇÑо¿ñ²ðﱬ·¢ÆøÖÆÊ¹ÓÃ×î¶àµÄÖØ´ó²¿·ÖÐÔÄ£×Ó ÄÜ·ñ·ºÆðµãȼȡ¾öÓڴ̼¤Ò»Á¬Ê±¼ä¡¢Ç¿¶È¡¢´Ì¼¤¾àÀëʱ¼äµÈ²ÎÊý¡£±ê×¼µÄ´Ì¼¤Ìõ¼þΪµçÁ÷Ç¿¶È3mA£¬Ò»Á¬2Ã룬1´Î£¯ÈÕ£¨Ð¡Ê󣩣»8mA£¬Ò»Á¬4Ã룬2´Î£¯ÈÕ£¨´óÊ󣩣¬Ö±ÖÁ·ºÆð5¼¶±¬·¢£¬¼´±»ÒÔΪµÖ´ïÍêÈ«µãȼ¡£Ñ¡È¡Ò»Á¬10´ÎµÖ´ï5¼¶±¬·¢µÄ´óÊóÓÃÓÚɸѡ¿¹²¡Ò©¼°»úÖÆÑо¿¡£ µãȼÀú³Ì¿É·ÖΪ6¸ö½×¶Î£º¢Ùͬ²àÃæ²¿³é´¤£»¢ÚÁ½²àÃæ²¿³é´¤£»¢Ûò¥Ê×£»¢Ü¶Ô²àǰ֫·ºÆðÕóÂΣ»¢ÝÕ¾Á¢°éÕóÂÎÐÔÌøÔ¾£»¢Þˤµ¹°éÈ«Éíǿֱ£­ÕóÂα¬·¢¡£µç´Ì¼¤ÄÔ²¿Ðí¶à²¿Î»¿ÉÒýÆðµãȼ£¬×îÒ×µãȼ²¿Î»ÎªÐÓÈʺˣ¬Æä´ÎΪÐÂÆ¤ÖÊÇøºÍº£Âí¡£

2. »¯Ñ§µãȼģ×Ó£­ÂíÉ£ÄÚõ¥µãȼģ×Ó ÂíÉ£ÄÚõ¥(coriaria lactone)1.25~1.75mg/kg¼¡ÄÚ»ò¸¹Ç»×¢É䣬1´Î£¯84Сʱ£¬Æ½¾ùΪ15´Î(7~20´Î)¡£µÚ8´Î¸øÒ©ºó£¬¶¯Îï·ºÆð×¢ÊÓ¡¢ºôÎü¼±´Ù¡¢Íâ¶ú¾²ÂöÀ©ÕÅ£¬Ö®ºóÉú³¤ÎªÔ˶¯²»Ð­µ÷¡¢Ã沿³é´¤¡¢´¥Ðë²ü¶¶¡¢Ç°Ö«³é¶¯£¨±¬·¢¼¶±ðΪ1~3¼¶£©£¬°éÓм¬²¨ºÍ¶à¼¬²¨¡£ÍêÈ«µãȼ´óÊóÌåÏÖΪվÁ¢°éË«ÉÏÖ«³é¶¯(4¼¶)ºÍʧȥ×ËÊÆÆ½ºâ¡¢Ë¤µ¹(5¼¶£©£¬×îÖÕÌåÏÖΪȫÉíǿֱ£­ÕóÂα¬·¢£¬Ò»Á¬10~20Ã룬ÄÔµçͼ(EEG)ÌåÏÖΪ¸ß²¨·ù²¡ÐԷŵç¡£¸ÃÄ£×Ó²¡Àí¸Ä±äÖ÷ҪΪº£ÂíÇøÐÇÐνºÖÊϸ°ûÏÔ×űäÐÔ¡¢»µËÀ£¬ÌáÐÑÂíÉ£ÄÚõ¥¶ÔÐÇÐνºÖÊϸ°ûºÍ´óÄÔÆ¤ÖÊϸ°ûÓÐËðÉËÐÔ×÷Ó㬸ÃËðÉË¿ÉÄÜÔÚÓÕµ¼ñ²ðﱬ·¢ÖÐÆðÒ»¶¨×÷Ó᣸ÃÄ£×Ó½¨ÉèÇáÓ¯£¬µãȼЧÂʸߣ¬éæÃüÂʵͣ¬ÊÊÓÚÍÆ¹ã¡£

¡¾Ä£×ÓÆÀ¹ÀºÍÓ¦Óá¿£º

µãȼģ×ÓÐÐΪ¹æ·¶£¬¿É¿ØÐÔºÍÖØ¸´ÐԺã¬Ò×ÓÚ¶ÏÓ붨Á¿Ñо¿¡£ÎªÑо¿ÈËÀàñ²ðﱬ·¢ÆøÖÆ¡¢Ò©ÎïÓÐÓÃÐÔ¼°¿¹ñ²ðïÒ©ÎïÄÍÒ©µÄ·Ö×Ó»úÖÆ£¬Ñ°ÕÒеĻò¸üÓÐÓõÄÖÎÁÆÒ©ÎÌṩÁËÒ»¸öÀíÏëµÄ¶¯ÎïÄ£×Ó¡£´ËÄ£×ӽϺõØÄ£ÄâÁËÈËÀàñ²ðﱬ·¢¡¢À©²¼ºÍÐγɵÄÈ«Àú³Ì£¬Òò´Ë£¬±»ÒÔΪÊǸüΪ¿¿½üÈËÀàñ²ðïµÄÂýÐÔÄ£×Ó¡£µãȼģ×Ó±»ÆÕ±éÓÃÓÚѰÕÒÖÎÁƲ¿·ÖÐÔ±¬·¢µÄÐÂÒ©£¬ÔÚµãȼÀú³ÌÖÐÔ¤ÏȸøÓèËù²âÊÔµÄÒ©ÎÊÓ²ì¸ÃÒ©ÎïÄÜ·ñ×èÖ¹»òÑÓ»ºµãȼÕ÷ÏóµÄ±¬·¢£¬ÒÔ¼ì²â¸ÃÒ©ÊÇ·ñ¾ßÓп¹¾ªØÊ×÷Óúͣ¨»ò£©¿¹ñ²ðïÔîÐγɵÄ×÷Óá£

 

²Î¿¼ÎÄÏ×£º

1.Andrè V, Dube C, Francois J, et al. Pathogenesis and pharmacology of epilepsy in the lithium-pilocarpine model. Epilepsia,2007,48 (Suppl 5):41-47

2.Gareri P, Condorelli D, Bellua.rdo N, el al. Antiabsence effects of carbenoxolone in two genetic animal models of absence epilepsy (WAG/Rij rats and lh/lh mice).Neuropharmacology, 2005, 49 (4):551-563

3.Holmes GL. Animal model studies application to human patients. Neurology, 2007, 69 (24 Suppl 3): S28-32

4.Jefferys JG. Models and mechanisms of experimental epilepsies. Epilepsia, 2003, 44 (Suppl 12):44-50

5.Löscher W,Leppik IE. Critical re-evaluation of previous preclinical strategies for the cliscovery and the development of new anliepileplic drugs. Epilepsy Res, 2002, 50 (1-2):17-20

6.Löscher W,Schmidt D.Stralegies in aatiepileptic drug development: is rational drug design superior to random screening and structural variation?Epilepsy Res, 1994, 17 (2):95-134

7.Wang Y, Zhou D, Wang B, el al. A kindling model of pharmacoresislanl temporal lobe epilepsy in SpragueDawley rats induced by Coriaria lactone and its possible mechanism. Epilepsia,2003,44(4):475-488

8.White HS. Preclinical development of antiepileptic drugs: past, present, and future directions. Epilepsia, 2003, 44 (Suppl 7):2-8

¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿